← Back to Search

Small Molecule Drug

APX3330 for Diabetic Retinopathy (ZETA-1 Trial)

Phase 2
Waitlist Available
Research Sponsored by Ocuphire Pharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights

ZETA-1 Trial Summary

This trial will test a new drug to see if it is safe and effective in treating diabetic retinopathy and diabetic macular edema.

Eligible Conditions
  • Diabetic Retinopathy
  • Diabetic Macular Edema

ZETA-1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent of Subjects with an improvement in Diabetic Retinopathy Severity Score (DRSS)
Secondary outcome measures
Mean Change in Best-Corrected Visual Acuity (BCVA)
Mean Change in Central Subfield Thickness (CST)
Mean Change in Diabetic Retinopathy Severity Scale (DRSS) Score
+2 more

ZETA-1 Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: APX3330Experimental Treatment1 Intervention
Five 120 mg tablets will be taken by mouth as follows: 3 tablets every morning and 2 tablets every evening.
Group II: PlaceboPlacebo Group1 Intervention
Five 120 mg tablets will be taken by mouth as follows: 3 tablets every morning and 2 tablets every evening.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
APX3330
2021
Completed Phase 2
~130

Find a Location

Who is running the clinical trial?

Ocuphire Pharma, Inc.Lead Sponsor
10 Previous Clinical Trials
1,358 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many US-based sites are conducting this research project?

"Currently, 42 medical centres are distributing the treatment examined in this trial. These locations include Sacramento, McAllen and San Antonio as well as many other cities. It is beneficial to choose the nearest clinical site to reduce any travel burden if you decide to take part in this study."

Answered by AI

Are there any current opportunities to join this research endeavor?

"According to the clinical trials database, this medical trial is no longer in the recruitment phase. Initially posted on April 8th 2021 and last updated on April 28th 2022, it has been surpassed by 174 other active studies looking for participants."

Answered by AI

Can you quantify the risk of APX3330 for patients?

"Our team at Power judged APX3330's safety to be a 2 because it is currently in Phase 2, implying that while there are some data points supporting safety, no efficacy studies have been conducted."

Answered by AI

Who else is applying?

What state do they live in?
California
Texas
How old are they?
65+
18 - 65
What site did they apply to?
Clinical Site 12
Clinical Site 3
Clinical Site 2
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
2021. "Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04692688.
~26 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top